These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Hollander P Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341 [TBL] [Abstract][Full Text] [Related]
47. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Wierzbicki AS Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677 [TBL] [Abstract][Full Text] [Related]
48. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents. Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896 [TBL] [Abstract][Full Text] [Related]
50. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management? Jensen MD Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358 [TBL] [Abstract][Full Text] [Related]
51. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341 [TBL] [Abstract][Full Text] [Related]
52. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna. Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035 [No Abstract] [Full Text] [Related]
53. [Nutrition-obesity. Rimonabant and cardiovascular risk factors]. Vincent M; Golay A Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325 [TBL] [Abstract][Full Text] [Related]
54. [New therapeutic aspects for the control of risk factors in obesity]. Formiguera X; Sierra A Med Clin (Barc); 2007 Apr; 128(13):508-14. PubMed ID: 17419915 [TBL] [Abstract][Full Text] [Related]
55. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism. Andrikopoulos GK; Tzeis S Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590 [TBL] [Abstract][Full Text] [Related]
57. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Pi-Sunyer FX Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():135S-142S. PubMed ID: 16931495 [TBL] [Abstract][Full Text] [Related]
58. Obesity: a review of pathogenesis and management strategies. Kaila B; Raman M Can J Gastroenterol; 2008 Jan; 22(1):61-8. PubMed ID: 18209783 [TBL] [Abstract][Full Text] [Related]
59. [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)]. Wirth A MMW Fortschr Med; 2006 Nov; 148(46):17. PubMed ID: 17615781 [No Abstract] [Full Text] [Related]
60. [What do we know about obesity?]. Guagnano MT; Manigrasso MR; Marinopiccoli M; Davì G Clin Ter; 2007; 158(3):261-6. PubMed ID: 17612288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]